WO2003103675A3 - Combination treatments for purinoceptor-related disorders - Google Patents

Combination treatments for purinoceptor-related disorders Download PDF

Info

Publication number
WO2003103675A3
WO2003103675A3 PCT/US2003/017964 US0317964W WO03103675A3 WO 2003103675 A3 WO2003103675 A3 WO 2003103675A3 US 0317964 W US0317964 W US 0317964W WO 03103675 A3 WO03103675 A3 WO 03103675A3
Authority
WO
WIPO (PCT)
Prior art keywords
purinoceptor
related disorders
combination treatments
treating
preventing
Prior art date
Application number
PCT/US2003/017964
Other languages
French (fr)
Other versions
WO2003103675A2 (en
Inventor
Constance N Wilson
Mark A Sirgo
Original Assignee
Endacea Inc
Constance N Wilson
Mark A Sirgo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endacea Inc, Constance N Wilson, Mark A Sirgo filed Critical Endacea Inc
Priority to AU2003237460A priority Critical patent/AU2003237460A1/en
Publication of WO2003103675A2 publication Critical patent/WO2003103675A2/en
Publication of WO2003103675A3 publication Critical patent/WO2003103675A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides methods of preventing and treating purinoceptor-related disorders comprising concurrently administering an A1 adenosine receptor antagonist or a P2x purinoceptor antagonist with an at least one additional active agent effective to treat purinoceptor-related disorders. The present invention also provides pharmaceutical formulations suitable for preventing and treating purinoceptor-related disorders.
PCT/US2003/017964 2002-06-06 2003-06-06 Combination treatments for purinoceptor-related disorders WO2003103675A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003237460A AU2003237460A1 (en) 2002-06-06 2003-06-06 Combination treatments for purinoceptor-related disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60/386,769 2002-06-06
US38676902P 2002-06-07 2002-06-07

Publications (2)

Publication Number Publication Date
WO2003103675A2 WO2003103675A2 (en) 2003-12-18
WO2003103675A3 true WO2003103675A3 (en) 2004-03-25

Family

ID=29736207

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/017964 WO2003103675A2 (en) 2002-06-06 2003-06-06 Combination treatments for purinoceptor-related disorders

Country Status (2)

Country Link
AU (1) AU2003237460A1 (en)
WO (1) WO2003103675A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522916B2 (en) 2007-12-21 2016-12-20 Constance Neely Wilson A1 adenosine receptor antagonists

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247639B2 (en) * 2003-06-06 2007-07-24 Endacea, Inc. A1 adenosine receptor antagonists
JP2007506804A (en) * 2003-06-09 2007-03-22 エンダセア， インコーポレイテッド A1 adenosine receptor antagonist
ES2223287B1 (en) * 2003-08-04 2006-04-16 Universidad Del Pais Vasco-Euskal Herriko Unibertsitatea COMPOUNDS FOR THE TREATMENT OF DEMIELINIZING AND AUTOIMMUNE DISEASES.
EP1738766A4 (en) * 2004-03-30 2010-05-12 Kyowa Hakko Kirin Co Ltd Preventive and/or therapeutic agent for disease accompanied by chronic muscle/skeleton pain
US9877967B2 (en) * 2010-01-26 2018-01-30 Endacea, Inc. Methods and pharmaceutical compositions for preventing and treating renal impairment
IT202000015817A1 (en) * 2020-07-01 2022-01-01 Giampietro Iachettini ADENOSINE FOR USE IN THE TREATMENT OF VIRAL INFECTIONS

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026728A1 (en) * 1994-03-30 1995-10-12 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US5733916A (en) * 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
WO1999034803A1 (en) * 1998-01-09 1999-07-15 The Trustees Of The University Of Pennsylvania Compositions and methods for use in ischemia-reperfusion and endotoxin-related tissue injury
WO1999038532A2 (en) * 1998-01-28 1999-08-05 Link Technology, Inc. Methods for the prevention and treatment of fibrosis and sclerosis
WO2002094317A1 (en) * 2001-05-18 2002-11-28 Endacea Inc. Methods and formulations of using a1 adenosine and p2x purinoreceptor antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026728A1 (en) * 1994-03-30 1995-10-12 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US5733916A (en) * 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
WO1999034803A1 (en) * 1998-01-09 1999-07-15 The Trustees Of The University Of Pennsylvania Compositions and methods for use in ischemia-reperfusion and endotoxin-related tissue injury
WO1999038532A2 (en) * 1998-01-28 1999-08-05 Link Technology, Inc. Methods for the prevention and treatment of fibrosis and sclerosis
WO2002094317A1 (en) * 2001-05-18 2002-11-28 Endacea Inc. Methods and formulations of using a1 adenosine and p2x purinoreceptor antagonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NEELY C ET AL: "A1 adenosine receptor antagonist, 8-benzyl-7,(2-(ethyl(2-hydroxyethyl )amino)-ethyl)theophylline, and/or the P2X purinoceptor antagonist, pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid block endotoxin-induced lung injury.", DRUG DEVELOPMENT RESEARCH, vol. 43, no. 1, January 1998 (1998-01-01), 6th International Symposium on Adenosine and Adenine Nucleotides: New Frontiers in the 3rd Millennium;Ferrara, Italy; May 19-24, 1998, pages 76, XP009016775, ISSN: 0272-4391 *
NEELY CONSTANCE F ET AL: "A-1 adenosine receptor antagonists block ischemia-reperfusion injury of the heart.", CIRCULATION, vol. 94, no. 9 SUPPL., 1996, pages II376 - II380, XP009017123, ISSN: 0009-7322 *
NEELY CONSTANCE F ET AL: "A-1-adenosine receptor antagonists block endotoxin-induced lung injury.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 272, no. 2 PART 1, 1997, pages L353 - L361, XP000901722, ISSN: 0002-9513 *
STEINMETZ M ET AL: "Influence of purinoceptor antagonism on diadenosine pentaphosphate-induced hypotension in anesthetized rats.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. UNITED STATES SEP 2000, vol. 294, no. 3, September 2000 (2000-09-01), pages 963 - 968, XP001154546, ISSN: 0022-3565 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522916B2 (en) 2007-12-21 2016-12-20 Constance Neely Wilson A1 adenosine receptor antagonists

Also Published As

Publication number Publication date
WO2003103675A2 (en) 2003-12-18
AU2003237460A1 (en) 2003-12-22

Similar Documents

Publication Publication Date Title
TW200500375A (en) Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
WO2000012110A3 (en) Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
MX2007005570A (en) Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases.
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
EP1348466A3 (en) Method for treating pain with adenosine-tetraphosphates
IL166761A0 (en) Use of CGRP antagonist compounds for treatment of psoriasis
SE0002754D0 (en) New pharmaceutical combination formulation and method of treatment with the combination
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
BR9914419A (en) Perception improvement therapy
WO2004038001A3 (en) Substituted tetracycline compounds for the treatment of malaria
NO20024646L (en) Combination therapies with vasculature-damaging activity
BR0200246A (en) Combination treatment for depression
EA200001010A1 (en) APPLICATION OF DEXMEDETOMIDINE FOR SEDATIVE IMPACT IN THE DEPARTMENT OF INTENSIVE THERAPY
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
TW200420290A (en) Methods for the treatment, prevention and management of macular degeneration
WO2003103675A3 (en) Combination treatments for purinoceptor-related disorders
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
BR0307022A (en) Method of treating a patient who needs analgesia
TR200103418T2 (en) Therapeutic use of melatonin.
BR0211855A (en) Drug and method for treating and improving restorative sleep quality
MXPA04002389A (en) Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic.
GB9930075D0 (en) Medicaments
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP